Tag Archives: ipilimumab

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma

Nivolumab + Ipilimumab Provides Long-Term Survival Benefit

Nivolumab + ipilimumab continues to provide a long-term survival benefit in malignant pleural mesothelioma. A new report shows a 3-year follow-up in the CheckMate Clinical Trial. Long-term clinical benefits remained the same for all patient groups. Background on the Nivolumab + Ipilimumab Treatment Two years ago, the FDA approved the combination of nivolumab + ipilimumab. It is the first-line treatment for patients with metastatic non-small cell lung cancer. The CHECKMATE randomized multi-part trial investigated the effectiveness. The trial showed a significant improvement in patient survival. Today, this treatment combination improves patient survival rates over chemotherapy. Mesothelioma patients showed an improved survival using this line of treatment. A new report from the Annals of Oncology describes updated data with at least … Continue reading Nivolumab + Ipilimumab Provides Long-Term Survival Benefit in Malignant Pleural Mesothelioma »

Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good

Yervoy and Opdivo for mesothelioma

Three years after the last patients enrolled in the clinical trial of Yervoy and Opdivo for mesothelioma, survival results still look promising for this immunotherapy treatment.  Researchers presented an update of the CheckMate 743 trial at the recent virtual conference of the European Society for Medical Oncology (ESMO). The team found that more than 23% of patients on Yervoy and Opdivo for mesothelioma were still alive at three years. Only 15% of the chemotherapy group were still living.  Immunotherapy for Malignant Mesothelioma Alimta (pemetrexed) was the first drug to receive FDA approval for mesothelioma chemotherapy. The FDA approved it in 2004.  Before Alimta, patients had even fewer options that they do today. Most mesothelioma patients now start treatment with a … Continue reading Yervoy and Opdivo for Mesothelioma: Three Year Results Still Look Good »

Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care

Two immunotherapy drugs could become the new standard of care for people with non-epithelioid mesothelioma.  All forms of malignant mesothelioma are deadly. But people with a non-epithelioid mesothelioma subtype are less likely to respond to standard treatments. Their variety of mesothelioma is especially resistant to chemotherapy with cisplatin and Alimta. This has been the mainstay of pleural mesothelioma treatment since 2004. But a new trial shows two immunotherapy drugs extended mesothelioma survival better than chemotherapy. This could be especially good news for patients with non-epithelioid mesothelioma.  Checkpoint Inhibitors for Mesothelioma Most people with pleural mesothelioma start with chemotherapy. Chemotherapy can often extend life by a few months. It is most beneficial for patients with epithelioid mesothelioma. But this approach does … Continue reading Non-Epithelioid Mesothelioma: Immunotherapy Combo Could be the New Standard of Care »